• Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Jounce Therapeutics Inc.

Headquarters: Cambridge, MA, United States
Website: N/A
Year Founded: 2013
Status: Acquired

BioCentury | Apr 7, 2025
Deals

Latest capsid deal gives a lifeline to Sangamo: Deals Report

Plus: Sanofi gains license to another Nurix program; Allakos takes Tang/Concentra buyout offer
Read More
BioCentury | Apr 7, 2025
Management Tracks

Hodits joining Angelini venture unit

Plus: Zenas taps Tesaro vet Lakin for CSO job; Lift hires Exley
Read More
BioCentury | Feb 25, 2025
Deals

Counteroffer from Tang-backed Concentra could scuttle Acelyrin-Alumis: Deals Report

Plus Radiance gets ROR1 ADC from Cspc, Astrazeneca buys Fibrogen’s China subsidiary and more
Read More
BioCentury | Mar 27, 2024
Management Tracks

Furuta to become CFO at Takeda

Plus: IDRx names Kerstein CMO and updates from Transgene, Noetik, Egle and MannKind
Read More
BioCentury | Jan 24, 2024
Management Tracks

Markison to succeed Heino as Lantheus CEO

Plus: Lisa Olson becomes CEO of Enthera, and updates from Bayer, Neumora, PDS and more
Read More
BioCentury | Jul 28, 2023
Deals

Biotech reverse mergers growing amid improving market conditions

Are 2023’s reverse mergers another sign of an improving biotech environment?
Read More
BioCentury | Jul 11, 2023
Management Tracks

Billy Cho joins CBC as senior managing director

Plus: Birchenough becomes chairman of global healthcare at Barclays, and updates from EyePoint, Replicate, MBX, Voyager and more
Read More
BioCentury | Mar 28, 2023
Product Development

March 27 Quick Takes: Big gain for Novartis on Kisqali readout

Plus: SR One closes $600M second fund and updates from Vertex, CRISPR; Merck KGaA, Pfizer and more 
Read More
BioCentury | Mar 16, 2023
Deals

March 15 Quick Takes: Rival bid could upend Redx-Jounce deal

Plus: Dermavant’s Vtama meets Phase III endpoints, and updates from CMS, Aitia, Bellicum and more
Read More
BioCentury | Feb 23, 2023
Deals

Redx adds U.S. office while Jounce shareholders eye CVR’s upside in merger

Combined company will prioritize U.K. company’s ROCK2 program as deal adds to Redx’s balance sheet
Read More
Items per page:
1 - 10 of 79